Blog Archives

President’s Update – MassBio in 2014: A Year in Review

MassBio PresidentDear Readers,

As 2014 comes to a close and we prepare for what’s coming in 2015, I want to thank you for your involvement and support and reflect on 2014 with a Year in Review highlighting our biggest focus areas of 2014.

1. Shaping the Future

This year, MassBio released Impact 2020, a strategic report on the state of the biotechnology and life sciences cluster in Massachusetts. Impact 2020 calls Massachusetts stakeholders across industry, academia, healthcare networks, payers and government to:impact

  • Drive the conversation on defining value and reward for innovation in the era of outcomes-focused medicine;
  • Seize a leadership opportunity at the intersection of tech and life sciences;
  • Evolve funding models for early-stage companies and innovative ideas;
  • Improve workforce development to ensure a workforce trained for the jobs of the future & support downstream expansion; and
  • Highlight patient stories to showcase the impact of innovation taking place in Massachusetts.

Impact 2020 will guide MassBio’s initiatives in the next five years, and MassBio has already started integrating the report into our programs and services.

2. Defining Value, Focusing on the Patient

defining valueMassBio joined the conversation on defining value at our Policy Leadership Breakfast in January, where a panel of experts discussed how medical innovation can exist in a new era of healthcare cost containment. We continued the discussion at the 2014 MassBio Annual Meeting and through the year with a Forum series called The Future of Biotech: Defining & Building Value in Healthcare.

No conversation on value would be complete without the patient voice, so in 2014 MassBio hosted its first ever Patient Advocacy Summit. The sold-out Summit brought industry leaders and patient advocates together to examine ways in which life sciences companies can more fully incorporate the patient voice into the work they do throughout the drug development cycle. MassBio will continue educate and support members as they seek to define and demonstrate the value of new treatments.

3. Catalyzing Innovation

catalyzing

MassBio supports innovation at its earliest stages. This year we matched 12 startups with teams of mentors through the MassCONNECT program. It was a banner year for MassCONNECT graduates, who have made deals with biopharma partners, won international business plan competitions and reached product milestones. We also continued to host Pharma Days, our customized, invitation-only partnering events designed to ensure pharma companies meet the right biotech and startup partners.

The findings of Impact 2020 and our annual Industry Snapshot demonstrate that early-stage funding is at a critical juncture. To start needed conversations on this, we hosted a Beg, Borrow & Crowdsource panel discussion at the Annual Meeting and three MassBio Twitter Chats (new in 2014!) on entrepreneurism, seed- and early-stage funding.

We continue to roll out unique, targeted events to convene our members with shared interests, including a new legal workshop in partnership with the American Bar Association, our annual CSO Roundtable, and a BIO Convention debrief.
Read the rest of this entry

How Can Industry & Academia Fill Middle-Skills Jobs?

To probe the issues behind the middle-skills gap, Accenture, Burning Glass Technologies and Harvard Business School (HBS) launched a collaborative research partnership in 2013 under the umbrella of HBS’ U.S. Competitiveness Project. The various research studies and analyses of this project are being driven by the principle that the “United States is a competitive location to the extent that companies operating in the U.S. are able to compete successfully in the global economy while supporting high and rising living standards for the average American.”

View full report here.

Much has been written about the shortfall in high-end skills, particularly in the STEM fields (Science, Technology, Engineering and Math). Less attention has been paid to so-called “middle-skills” jobs—those that require more than a high school diploma but less than a four-year degree. How can industry help lower the number of STEM “middle-skill” jobs being left unfilled?

It is crucial for academia to create opportunities for students to experience internships and work-simulations in order to fully understand and prepare for these middle-skills jobs that they are studying to fill. Ten community colleges were recognized yesterday by the Massachusetts Life Sciences Education Consortium for having associate degree and certificate programs that give students a work opportunity. This event was held at Shire in Lexington, Massachusetts. View the online album here.

Closing-The-Middle-Skills-Gap-What-Businesses-Should-Do-Infographic

 

A lack of communication between academia and industry is causing a big problem in filling these jobs. One-third of HR executives in the Accenture survey noted that while they could find skilled workers, many candidates lacked foundational skills such as an understanding of what makes an effective and reliable employee.
Read the rest of this entry

Wishing You a Happy Thanksgiving

The MassBio & MassBioEd teams have plenty to give thanks for this holiday season.

We are thankful for a dynamic, inspiring community of scientists, life sciences leaders, policy leaders, and patient advocates. We are thankful for the work you do each day to ensure our family and friends can lead fuller, healthier lives.

We are thankful for your support of our initiatives as we strive to enhance the life sciences super-cluster so it continues to be an ecosystem that allows and encourages the the development of critical new science, technology and medicines that benefit people worldwide.

We are also thankful for your support of the MassBioEd Foundation and like-minded organizations committed to enhancing science and biotechnology education in Massachusetts and developing the life sciences workforce of the future.

We wish you and your families a happy, healthy Thanksgiving holiday!

IMG_0005 edit

 

Join the Conversation: Biotech 101 for Non-Scientists

allie4By Allie Rocovich, Communications Assistant at MassBio/MassBioEd. View her LinkedIn page here.

What’s more intimidating than entering a conversation with people that are talking about something you know nothing about? I can’t think of anything. And our career is the biggest ‘conversation’ we are going to take part in throughout our lives. So why not be ready, know the jargon, and be able to take part like we all want to, for the sake of our self-esteem, knowledge, and overall career satisfaction?

It’s scary, entering a new job, especially if you’re making a career move into an industry you aren’t schooled in. Biotech is hard. Not only is the actual content – the science – difficult, but there are so many stakeholders in the industry that knowing the science isn’t even all there is to it. That’s where we, the finance, business, marketing, operations, economics, communications, policy, government, management, IT, sales, public relations and human resources professionals find ourselves useful, but we’re hesitant. We want in on the conversation, but don’t speak the language.

Biotech 101 is our in. It’s the dictionary, the introductory biology class we never took, the shameless question-and-answer. Not to mention it’s totally up-to-date, and there are ALWAYS new things happening in the life sciences, it’s the nature of the industry. So when I, a Communications Assistant at MassBio, took Biotech 101, I got to learn about the latest topic in and outside of the office: Ebola.

Biotech 101 is designed to accommodate open discussion and questions, and because most of the people gathered for Biotech 101 were heavily social and relationship-driven professionals, there was great discussion. This helped break down the conversation barrier that a lack of science background can create in the lab, office, or wherever you spend your 9-5. It’s comfortable. Donald Kirsch, bio/pharmaceutical industry consultant and Harvard Extension School professor, lectured us while prompting us with questions that related directly to our respective roles. We got our questions answered (finally!).

Read the rest of this entry

Top 5 News 11/1/14 – 11/7/14

Top 5 logo1) With change of governors, a shift in approach to the economyBoston Globe, November 7, 2014
The election of Charlie Baker probably means a shift in the state’s approach to the economy after eight years with a governor who viewed and used government as a catalyst for economic growth. Baker is likely to return to the philosophy and policies of his Republican predecessors, who believed that the best way for government to boost jobs and the economy is to largely get out of the way. That approach is in sharp contrast to that of Governor Deval Patrick, who targeted industries that his administration viewed as promising, such as biotechnology and clean energy, and supported them with taxpayer money and other initiatives. Link

2) Boston Children’s “Innovation Tank” yields two first-place winners, Boston Business Journal, November 2, 2014
Multimillionaire and entrepreneur Daymond John sat listening to innovators making impassioned pleas about their products, asking them questions about sales data and evidence of proof of concept.Yet instead of a panel with four other millionaires, he sat with Boston innovators and venture capitalists, and instead of being hosted by ABC, the event was held by the Boston Children’s Hospital Global Pediatric Innovation Summit. Link

3) Bristol-Myers Squibb Company (BMY) Strikes Deal Worth $444 Million With Galecto BiotechBioSpace, November 3, 2014
Bristol-Myers Squibb Company (BMY) will acquire Danish firm Galecto Biotech for $444 million in a bid to gain worldwide rights to its lead asset, pulmonary fibrosis drug TD139, the two companies said in a statement Monday. The new deal will consist of total aggregate payments which have the potential to reach $444 million, including an option fee, an option exercise fee and built-in clinical and regulatory milestone payments. Link

4) Karyopharm settles into new home, gears up for biggest drug trial yetBoston Business Journal, November 4, 2014
Since moving to its new, larger headquarters in Newton this summer, Karyopharm Therapeutics has been readying for its largest-ever clinical trial involving blood-cancer patients. And next month, investors will get a preview of the results from an earlier trial. Link

5) New Massachusetts Life Sciences Center grant program to fund milestone achievement by early-stage companiesMassBio, November 7, 2014
The Massachusetts Life Sciences Center (MLSC) announced the launch of a new grant program today at MassMEDIC’s MedTech Showcase.  The Life Sciences Milestone Achievement Program (MAP) will award early-stage life sciences companies in Massachusetts with funding necessary to perform and complete essential value-creating milestones. Link